Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 30:13:975367.
doi: 10.3389/fimmu.2022.975367. eCollection 2022.

Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications

Haixia Zhang  1   2 , Ke Yang  1 , Feng Chen  1 , Qianqian Liu  1 , Jingyu Ni  1 , Weilong Cao  1 , Yunqing Hua  1 , Feng He  3 , Zhihao Liu  4 , Lan Li  1   4   5 , Guanwei Fan  1   3
Affiliations
Review

Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications

Haixia Zhang et al. Front Immunol. .

Abstract

The CCL2-CCR2 axis is one of the major chemokine signaling pathways that has received special attention because of its function in the development and progression of cardiovascular disease. Numerous investigations have been performed over the past decades to explore the function of the CCL2-CCR2 signaling axis in cardiovascular disease. Laboratory data on the CCL2-CCR2 axis for cardiovascular disease have shown satisfactory outcomes, yet its clinical translation remains challenging. In this article, we describe the mechanisms of action of the CCL2-CCR2 axis in the development and evolution of cardiovascular diseases including heart failure, atherosclerosis and coronary atherosclerotic heart disease, hypertension and myocardial disease. Laboratory and clinical data on the use of the CCL2-CCR2 pathway as a targeted therapy for cardiovascular diseases are summarized. The potential of the CCL2-CCR2 axis in the treatment of cardiovascular diseases is explored.

Keywords: CCL2; CCR2; cardiovascular disease; chemokine; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
CCL2-CCR2 network and expression in human tissues. (A) Chemokines and their receptor networks associated with the CCL2-CCR2 axis (9). The chemokine family is a huge system of ligands and GPCRS. In this network, CCL2 can bind to a variety of receptors, including the classical chemokine receptors (shaded in pink) CCR1, CCR2, CCR4 and the atypical chemokine receptors (shaded in gray) ACKR1, ACKR2. CCR2 can also bind to a variety of ligands (in red), including CCL2, CCL7, CCL8, CCL11, CCL13, CCL16, CCL26. (B) CCL2 and CCR2 RNA expression in human tissues, X-axis represents the consensus data based on normalized expression (nTPM) values (data from https://www.proteinatlas.org).
Figure 2
Figure 2
Schematic diagram of the CCL2-CCR2 axis and its signaling pathway. CCR2 is a G PCR. Upon binding of CCR2 to CCL2, a range of signaling downstream is activated, for instance, the JAK/STAT pathway, MAPK pathway and PI3K/Akt pathway. A variety of transcription factors and genes are then activated to participate in cytokine production, cell growth and differentiation, cell survival, migration and apoptosis.This figure was created with BioRender.com.
Figure 3
Figure 3
Role of the CCL2-CCR2 axis in cardiovascular disease. The CCL2-CCR2 axis fosters monocyte mobilization from the bone marrow and recruits circulating monocytes to the site of the lesion. In plaques, monocytes are differentiated to macrophages, which proliferate, become foam cells, and coordinate the inflammatory response (A). In infarcted myocardial tissue, monocytes are recruited and differentiated into macrophages that influence MI disease progression (B). In hypertension, monocytes infiltrate into the vascular adventitia, perivascular fat, heart, kidney, and brain, and are involved in elevated blood pressure and end-organ damage (C). In cardiomyopathies (dilated cardiomyopathy as an example), monocytes infiltrate and differentiate into macrophages in the damaged myocardium and participate in the development and progression of cardiomyopathies (D). This figure was created with BioRender.com.
See this image and copyright information in PMC

References

    1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet (London England) (2020) 396(10258):1204–22. doi: 10.1016/s0140-6736(20)30925-9 - DOI - PMC - PubMed
    1. Fegers-Wustrow I, Gianos E, Halle M, Yang E. Comparison of American and European guidelines for primary prevention of cardiovascular disease: Jacc guideline comparison. J Am Coll Cardiol (2022) 79(13):1304–13. doi: 10.1016/j.jacc.2022.02.001 - DOI - PubMed
    1. Liberale L, Montecucco F, Schwarz L, Lüscher T, Camici G. Inflammation and cardiovascular diseases: Lessons from seminal clinical trials. Cardiovasc Res (2021) 117(2):411–22. doi: 10.1093/cvr/cvaa211 - DOI - PubMed
    1. Liberale L, Badimon L, Montecucco F, Lüscher T, Libby P, Camici G. Inflammation, aging, and cardiovascular disease: Jacc review topic of the week. J Am Coll Cardiol (2022) 79(8):837–47. doi: 10.1016/j.jacc.2021.12.017 - DOI - PMC - PubMed
    1. Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New Engl J Med (2017) 377(12):1119–31. doi: 10.1056/NEJMoa1707914 - DOI - PubMed